Mesenchymal Stromal Cells' Therapy for Polyglutamine Disorders: Where Do We Stand and Where Should We Go?

Front Cell Neurosci · 2020 · PMC7573388 · PMID 33132851

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

( 2017 ) intravenously administered (5–7 × 10 7 ) allogeneic MSC derived from the adipose tissue (AD-MSC, single injection) into six patients with MJD and one with MSA, who showed a slight trend of improvement and stabilization of the disease according to the Scale for Assessment and Rating of Ataxia (SARA) and the sensory organization testing (SOT).

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.